Targeting Receptor Tyrosine Kinases in Solid Tumors
Author:
Publisher
Elsevier BV
Subject
Oncology,Surgery
Reference110 articles.
1. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors;Hamid;J Am Pharm Assoc (2003),2004
2. The protein tyrosine kinase family of the human genome;Robinson;Oncogene,2000
3. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers;Sharma;Curr Pharm Des,2009
4. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era;Cassier;Clin Cancer Res,2012
5. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis;Sivendran;Cancer Treat Rev,2012
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09
2. Tumor-induced neoangiogenesis and receptor tyrosine kinases – Mechanisms and strategies for acquired resistance;Biochimica et Biophysica Acta (BBA) - General Subjects;2019-07
3. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer;Bioscience Reports;2018-01-30
4. Principles of Kinase Inhibitor Therapy for Solid Tumors;Annals of Surgery;2017-02
5. Molecular genetics of soft tissue tumors;Modern Soft Tissue Pathology;2016-11-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3